“Representation in Alzheimer’s Studies Matter”

(ADNI) A significant challenge in developing therapies for Alzheimer’s disease that work for people of all ethnic and racial backgrounds is the recruitment and retention of traditionally underrepresented groups in clinical trials. Despite many studies suggesting African-Americans may be more susceptible to AD, they have been under-included in many prominent AD clinical trials. In fact, most of what we know about AD pathological changes comes almost exclusively from research studies of Caucasians. At the 2021 Clinical Trials in AD (CTAD2021) conference in Boston, researchers shared insights into what study sponsors can leverage to create a more diverse and inclusive clinical trial environment. Time to act now.

———
Chapter 6 “Lessons learned from major clinical trials conducted over the past decades.”

Read more: https://bairexmedical.com/chapter_6/